Page 80 - Read Online

Genovese et al. Cancer Drug Resist 2018;1:164-80 I http://dx.doi.org/10.20517/cdr.2018.10 Page 179

results from a unique large amplification of the 7q21 region. Genes Chromosomes Cancer 2006;45:495-508.
117. Kitada K, Yamasaki T. The MDR1/ABCB1 regional amplification in large inverted repeats with asymmetric sequences and
microhomologies at the junction sites. Cancer Genet Cytogenet 2007;178:120-7.
118. Kadioglu O, Efferth T. Peptide aptamer identified by molecular docking targeting translationally controlled tumor protein in leukemia
cells. Invest New Drugs 2016;34:515-21.
119. Chen GK, Lacayo NJ, Durán GE, Wang Y, Bangs CD, Rea S, Kovacs M, Cherry AM, Brown JM, Sikic BI. Preferential expression of
a mutant allele of the amplified MDR1 (ABCB1) gene in drug-resistant variants of a human sarcoma. Genes Chromosomes Cancer
2002;34:372-83.
120. Duesberg P, Li R, Sachs R, Fabarius A, Upender MB, Hehlmann R. Cancer drug resistance: the central role of the karyotype. Drug
Resist Updat 2007;10:51-8.
121. Katoh H, Shibata T, Kokubu A, Ojima H, Loukopoulos P, Kanai Y, Kosuge T, Fukayama M, Kondo T, Sakamoto M, Hosoda F,
Ohki M, Imoto I, Inazawa J, Hirohashi S. Genetic profile of hepatocellular carcinoma revealed by array-based comparative genomic
hybridization: identification of genetic indicators to predict patient outcome. J Hepatol 2005;43:863-74.
122. Mickley LA, Spengler BA, Knutsen TA, Biedler JL, Fojo T. Gene rearrangement: a novel mechanism for MDR-1 gene activation. J Clin
Invest 1997;99:1947-57.
123. Pang E, Hu Y, Chan KY, Lai PB, Squire JA, Macgregor PF, Beheshti B, Albert M, Leung TW, Wong N. Karyotypic imbalances and
differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells. Lab Invest 2005;85:664-74.
124. Kim IW, Han N, Kim MG, Kim T, Oh JM. Copy number variability analysis of pharmacogenes in patients with lymphoma, leukemia,
hepatocellular, and lung carcinoma using the cancer genome Atlas data. Pharmacogenet Genomics 2015;25:1-7.
125. Bonte D, Lindvall C, Liu H, Dykema K, Furge K, Weinreich M. Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell
lines is correlated with p53 inactivation. Neoplasia 2008;10:920-31.
126. Chao CC, Ma CM, Lin-Chao S. Co-amplification and over-expression of two mdr genes in a multidrug-resistant human colon carcinoma
cell line. FEBS Lett 1991;291:214-8.
127. Cheng AN, Jiang SS, Fan CC, Lo YK, Kuo CY, Chen CH, Liu YL, Lee CC, Chen WS, Huang TS, Wang TY, Lee AY. Increased Cdc7
expression is a marker of oral squamous cell carcinoma and overexpression of Cdc7 contributes to the resistance to DNA-damaging
agents. Cancer Lett 2013;337:218-25.
128. Finalet Ferreiro J, Rouhigharabaei L, Urbankova H, van der Krogt JA, Michaux L, Shetty S, Krenacs L, Tousseyn T, De Paepe P,
Uyttebroeck A, Verhoef G, Taghon T, Vandenberghe P, Cools J, Wlodarska I. Integrative genomic and transcriptomic analysis identified
candidate genes implicated in the pathogenesis of hepatosplenic T-cell lymphoma. PLoS One 2014;9:e102977.
129. Hansen SN, Ehlers NS, Zhu S, Thomsen MB, Nielsen RL, Liu D, Wang G, Hou Y, Zhang X, Xu X, Bolund L, Yang H, Wang J, Moreira J,
Ditzel HJ, Brünner N, Schrohl AS, Stenvang J, Gupta R. The stepwise evolution of the exome during acquisition of docetaxel resistance
in breast cancer cells. BMC Genomics 2016;17:442.
130. Litviakov NV, Cherdyntseva NV, Tsyganov MM, Slonimskaya EM, Ibragimova MK, Kazantseva PV, Kzhyshkowska J, Choinzonov EL.
Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to
neoadjuvant chemotherapy. Oncotarget 2016;7:7829-41.
131. Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn
KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group,
Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S,
O’Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller
DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ,
Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R,
Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C,
Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD. Whole-genome characterization of chemoresistant ovarian
cancer. Nature 2015;521:489-94.
132. Torigoe K, Sato S, Kusaba H, Kohno K, Kuwano M, Okumura K, Green ED, Tsui LC, Scherer SW, Schlessinger D, Wada M. A YAC-
based contig of 1.5 Mb spanning the human multidrug resistance gene region and delineating the amplification unit in three human
multidrug-resistant cell lines. Genome Res 1995;5:233-44.
133. Yabuki N, Sakata K, Yamasaki T, Terashima H, Mio T, Miyazaki Y, Fujii T, Kitada K. Gene amplification and expression in lung cancer
cells with acquired paclitaxel resistance. Cancer Genet Cytogenet 2007;173:1-9.
134. Januchowski R, Sterzyńska K, Zawierucha P, Ruciński M, Świerczewska M, Partyka M, Bednarek-Rajewska K, Brązert M, Nowicki
M, Zabel M, Klejewski A. Microarray-based detection and expression analysis of new genes associated with drug resistance in ovarian
cancer cell lines. Oncotarget 2017;8:49944-58.
135. Lee S, Kim K, Ho JN, Jin H, Byun SS, Lee E. Analysis of resistance-associated gene expression in docetaxel-resistant prostate cancer
cells. Oncol Lett 2017;14:3011-8.
136. Sasi NK, Bhutkar A, Lanning NJ, MacKeigan JP, Weinreich M. DDK Promotes Tumor Chemoresistance and Survival via Multiple
Pathways. Neoplasia 2017;19:439-50.
137. Genovese I, Ilari A, Assaraf YG, Fazi F, Colotti G. Not only P-glycoprotein: amplification of the ABCB1-containing chromosome region
7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. Drug
Resist Updat 2017;32:23-46.